NOVAVAX
(NASDAQ: NVAX)

Novavax, Inc. (Novavax) is a clinical stage biopharmaceutical company. The Company focuses on developing recombinant vaccines. The Company�s technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs). The Company's vaccine candidates are genetically engineered three-dimensional nanostructures, which incorporate immunologically important recombinant proteins. In July 2013, Novavax acquired approximately 97.4% of shares in Isconova AB.

7.830 s

-0.250 (-3.09%)
Range 7.940 - 8.130   (2.39%)
Open 7.940
Previous Close 8.080
Bid Price 8.030
Bid Volume 8
Ask Price 8.010
Ask Volume 22
Volume 2,686,123
Value -
Remark s
Delayed prices. Updated at 13 Feb 2025 05:00.
Data powered by
View All Events

About Novavax

Novavax, Inc. (Novavax) is a clinical stage biopharmaceutical company. The Company focuses on developing recombinant vaccines. The Company�s technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs). The Company's vaccine candidates are genetically engineered three-dimensional nanostructures, which incorporate immunologically important recombinant proteins. In July 2013, Novavax acquired approximately 97.4% of shares in Isconova AB.

Loading Chart...

Please login to view stock data and analysis